Talabostat SPA "Unnecessary" Given Available Cancer Guidance – Point
This article was originally published in Pharmaceutical Approvals Monthly
A special protocol assessment was "unnecessary" for Phase III trials of Point Therapeutics’ oncologic talabostat given the availability of "clear guidance" on cancer trial endpoints from FDA, Chief Development Officer Margaret Uprichard told a clinical update teleconference Jan. 31.
You may also be interested in...
Cancer trials need new methods of measuring progression, FDA guidance says. Draft document on clinical trial endpoints for cancer drugs advocates survival as “gold standard,” but discusses value of progression assessment as potential surrogate marker
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011